Lactic Dehydrogenase in Cerebrospinal Fluid May Differentiate Between Structural and Non-structural Central Nervous System Lesions in Patients with Diminished Levels of Consciousness

Vazquez, Jorge A.; Adducci, Maria del Carmen; Monzón, Daniel Godoy; Iserson, Kenneth V.

doi:10.1016/j.jemermed.2008.04.032

Cited by 12 publications

(7 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other problem of this study was a wide range of valuesin the 95% confidence interval due to the low numberof patients recruited during the research period. However, other studies havefound results similar to ours (9,10,11). Larger, multi-center studies may beneeded to more adequately assess the applicability ofemergency department obtained CSF-LDH as a clinical tool.…”

Section: Limitationssupporting

confidence: 89%

Assessment of Lactic Dehydrogenase in Cerebrospinal Fluid to Differentiate between Structural and Non-Structural Central Nervous System Lesions in Patients with Diminished Level of Consciousness

2017

IJSR

View full text Add to dashboard Cite

Abstract:Although both metabolic and structural abnormalities have devastating effect on the CNS, their treatment approaches and prognoses vary considerably. This study was conducted among 53 patients with diminished level of consciousness and CSF was analyzed for quantitative LDH(IU/L) value. In our study mean CSF-LDH was 25.19 ± 12.92 in patients with non-structural lesion and 86.53 ± 32.09 in patients with structural lesion of brain and difference was statistically highly significant (p<0.001). So CSF-LDH values can be used to differentiate between patients with structural pathology and those with metabolic disturbances.

show abstract

Section: Limitationssupporting

confidence: 89%

Assessment of Lactic Dehydrogenase in Cerebrospinal Fluid to Differentiate between Structural and Non-Structural Central Nervous System Lesions in Patients with Diminished Level of Consciousness

2017

IJSR

View full text Add to dashboard Cite

show abstract

“…Similarly, LDH (EC 1.1.1.27 & EC1.1.1.28), which catalyzes the interconversion of pyruvate and lactate, is ubiquitously released from all cells after damage to the plasma membrane. LDH is thought to be a biochemical index of neuronal cytotoxicity [33] with elevations in a wide array of neurological disorders including meningitis [34], prion disease [35], leukemia [36], trauma [37], infantile spasms [38], stroke [31] and canine GM1 gangliosidosis [21]. LDH has been used to distinguish various neurological disorders [37,39].…”

Section: Discussionmentioning

confidence: 99%

Biomarkers for disease progression and AAV therapeutic efficacy in feline Sandhoff disease

Bradbury

Gray‐Edwards

Shirley

et al. 2015

Experimental Neurology

View full text Add to dashboard Cite

The GM2 gangliosidoses, Tay-Sachs disease (TSD) and Sandhoff disease (SD), are progressive neurodegenerative disorders that are caused by a mutation in the enzyme β-N-acetylhexosaminidase (Hex). Due to the recent emergence of novel experimental treatments, biomarker development has become particularly relevant in GM2 gangliosidosis as an objective means to measure therapeutic efficacy. Here we describe blood, cerebrospinal fluid (CSF), magnetic resonance imaging (MRI), and electrodiagnostic methods for evaluating disease progression in the feline SD model and application of these approaches to assess AAV-mediated gene therapy. SD cats were treated by intracranial injections of the thalami combined with either the deep cerebellar nuclei or a single lateral ventricle using AAVrh8 vectors encoding feline Hex. Significantly altered in untreated SD cats, blood and CSF based biomarkers were normalized after AAV gene therapy. Also reduced after treatment were expansion of the lysosomal compartment in peripheral blood mononuclear cells and elevated activity of secondary lysosomal enzymes. MRI changes characteristic of the gangliosidoses were documented in SD cats and normalized after AAV gene therapy. The minimally invasive biomarkers reported herein should be useful to assess disease progression of untreated GM2 patients and those in future clinical trials.

show abstract

“…Lactate has been repeatedly demonstrated to be raised in cerebral ischaemia,16 17 peaking on the third day postinfarction18 with some degree of correlation with infarct size 19. There is a similar association with raised lactate dehydrogenase levels and structural brain pathology in acutely ill patients with a decreased level of consciousness20 that on reflection there may have been value in pursuing. We feel that in similar cases more comprehensive CSF analysis may be a worthwhile investigation for hunting chameleons, rather than simply for just ruling out mimics.…”

Section: Discussionmentioning

confidence: 83%

Hunting mimics and chameleons: diagnostic difficulties in atypical acute ischaemic stroke

Plummer

Hari-Bhaskar

2014

BMJ Case Reports

View full text Add to dashboard Cite

SUMMARYThe seemingly straightforward diagnosis of acute ischaemic stroke can be complicated by the presence of conditions presenting similarly to stroke, and atypical strokes presenting with confusing and non-classical signs. We present a diagnostic quest to disentangle the effects of a number of stroke mimics from those of an underlying bilateral cerebrovascular phenomena, where with appropriate treatment of the non-stroke conditions the patient was able to make a near complete neurological recovery. BACKGROUND

show abstract

Lactic Dehydrogenase in Cerebrospinal Fluid May Differentiate Between Structural and Non-structural Central Nervous System Lesions in Patients with Diminished Levels of Consciousness

Cited by 12 publications

References 29 publications

Assessment of Lactic Dehydrogenase in Cerebrospinal Fluid to Differentiate between Structural and Non-Structural Central Nervous System Lesions in Patients with Diminished Level of Consciousness

Assessment of Lactic Dehydrogenase in Cerebrospinal Fluid to Differentiate between Structural and Non-Structural Central Nervous System Lesions in Patients with Diminished Level of Consciousness

Biomarkers for disease progression and AAV therapeutic efficacy in feline Sandhoff disease

Hunting mimics and chameleons: diagnostic difficulties in atypical acute ischaemic stroke

Contact Info

Product

Resources

About